IKT Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
Dagens volum	98 979.00
Gjennomsnittsvolum	103 828
Markedsverdi	11.08M
EPS	$0 ( 2024-03-29 )
Neste inntjeningsdato	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0210 (1.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.54
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

Volum Korrelasjon

Lang: -0.10 (neutral)

Kort: 0.12 (neutral)

Signal:(46.584) Neutral

Inhibikase Therapeutics, Korrelasjon

10 Mest positive korrelasjoner
SVOK	0.82

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Inhibikase Therapeutics, Korrelasjon - Valuta/Råvare

0.36
( neutral )

0.08
( neutral )

0.00
( neutral )

0.60
( weak )

-0.28
( neutral )

-0.15
( neutral )

Inhibikase Therapeutics, Økonomi

Annual	2023
Omsetning:	$260 500
Bruttogevinst:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2023
Omsetning:	$260 500
Bruttogevinst:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2022
Omsetning:	$123 440
Bruttogevinst:	$116 717 (94.55 %)
EPS:	$-4.26

FY	2021
Omsetning:	$3.10M
Bruttogevinst:	$3.10M (100.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.